Replies to post #151218 on Biotech Values

[iwfal]

But in the final analysis, priority oncology products are still, to my mind, the most likely (on balance) to survive this purge, if only because their mission critical status will necessitate (and ultimately effect) a "compromise" with regulators.

Not sure that can be said with regard to any other high cost medical products.

I would strongly suggest you are missing the point. Almost all solid tumor oncology products provide, at best, a few months to a year or so extra survival. Is that really worth $500,000 (the cost of first line, second line and all the associated ancillary care (e.g. to deal with the side effects, in patient care, ...))

There is a good case that society cannot afford this - so yes, some patients will die sooner than they would have. But not a lot sooner.

Now - for some of these other cancer treatments (e.g. pona) that will get their big revenues by almost chronic treatments it is a different story.